The pioneering p300/CBP drug development company
Transforming outcomes and quality of life for people with cancer
Inobrodib; oral first-in-class p300/CBP inhibitor drug
CellCentric is a clinical stage biotech company; science driven, patient focused. We lead in the inhibition of p300/CBP to treat multiple specific cancer types. Our aim is to develop our first-in-class drug, inobrodib, as quickly and as effectively as possible for the benefit of patients.
About inobrodib
Inobrodib is a first-in-class oral anti-cancer drug developed from concept to clinical trials, by CellCentric. It has an innovative mechanism of action that targets twin tumour drivers, p300 and CBP. It is a small molecule, formulated as a capsule to be taken orally, with the potential to stop and reverse cancer growth in some of the most difficult to treat oncology indications.
Latest tweets from @CellCentric
Great to be in Chicago, #ASCO23. Continuing to progress inobrodib, our pioneering oral p300/CBP inhibitor drug. Making a difference to people with cancer.
Our Dir. Clinical Operations, Karen is speaking at the @ECMC_UK meeting on Wed. A great partnership, advancing innovative drugs for people with cancer.
Inobrodib, an easy to take oral drug for the widest R/R multiple myeloma community. Podcast recorded earlier this year: https://www.cellcentric.com/wp-content/uploads/2023/01/Optimumcellcentric-podcast_1_Mix4_AP_No-Intro-and-Outro.mp3
Great to be in Chicago, #ASCO23. Continuing to progress inobrodib, our pioneering oral p300/CBP inhibitor drug. Making a difference to people with cancer.
Our Dir. Clinical Operations, Karen is speaking at the @ECMC_UK meeting on Wed. A great partnership, advancing innovative drugs for people with cancer.
Inobrodib, an easy to take oral drug for the widest R/R multiple myeloma community. Podcast recorded earlier this year: https://www.cellcentric.com/wp-content/uploads/2023/01/Optimumcellcentric-podcast_1_Mix4_AP_No-Intro-and-Outro.mp3
Great to be in Chicago, #ASCO23. Continuing to progress inobrodib, our pioneering oral p300/CBP inhibitor drug. Making a difference to people with cancer.
Our Dir. Clinical Operations, Karen is speaking at the @ECMC_UK meeting on Wed. A great partnership, advancing innovative drugs for people with cancer.
Inobrodib, an easy to take oral drug for the widest R/R multiple myeloma community. Podcast recorded earlier this year: https://www.cellcentric.com/wp-content/uploads/2023/01/Optimumcellcentric-podcast_1_Mix4_AP_No-Intro-and-Outro.mp3